Published in Proc Natl Acad Sci U S A on August 15, 2000
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell (2007) 3.40
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene (2007) 1.69
ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol (2002) 1.55
Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol (2010) 1.31
Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol (2011) 1.23
Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res (2007) 1.21
Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila) (2011) 1.21
Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J Cell Biol (2001) 1.19
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res (2011) 1.10
Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene (2005) 1.04
Brain injury expands the numbers of neural stem cells and progenitors in the SVZ by enhancing their responsiveness to EGF. ASN Neuro (2009) 1.01
Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. Am J Pathol (2006) 0.98
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res (2013) 0.97
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice. Toxicol Appl Pharmacol (2008) 0.95
Prevention of ER-negative breast cancer. Recent Results Cancer Res (2009) 0.93
Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Res (2009) 0.89
Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells. J Mol Endocrinol (2008) 0.77
Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective. Proc Natl Acad Sci U S A (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A (1992) 8.59
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell (1986) 7.06
The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (1986) 5.77
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70
Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev (1997) 5.49
The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J (1999) 5.44
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med (1997) 5.10
The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 4.92
Tyrosine kinase inhibition: an approach to drug development. Science (1995) 4.82
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res (1996) 3.89
Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A (1998) 3.85
Specificity within the EGF family/ErbB receptor family signaling network. Bioessays (1998) 3.37
Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A (1993) 3.36
Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest (1997) 3.26
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell (1989) 2.74
Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature (1993) 2.63
Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell (1990) 2.63
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell (1989) 2.30
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell (1993) 1.97
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst (1997) 1.88
RAS pathways to cell cycle control and cell transformation. Front Biosci (1998) 1.60
The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem (1996) 1.58
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene (1994) 1.44
Activated neu induces rapid tumor progression. J Biol Chem (1996) 1.39
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem (1997) 1.38
Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol (1996) 1.36
Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. Cell Growth Differ (1990) 1.36
Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene (1989) 1.34
A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res (1996) 1.29
NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene (1996) 1.27
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem (2000) 1.26
Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene (1997) 1.24
New insights into the tumor suppression function of P27(kip1) Proc Natl Acad Sci U S A (1998) 1.17
MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol (1999) 1.10
Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst (1999) 0.95
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 5.84
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 5.19
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 5.00
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res (1999) 4.23
Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Nature (1987) 4.19
Trefoil peptides: less clandestine in the intestine. Science (1996) 3.60
Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol (2000) 3.55
Growth retardation and tumour inhibition by BRCA1. Nat Genet (1996) 3.47
A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys (1994) 3.29
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res (2001) 3.18
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology (2000) 2.99
Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med (1995) 2.74
Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (1989) 2.63
Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell (1990) 2.63
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res (1996) 2.58
Stereotactic radiosurgery for arteriovenous malformations of the brain. J Neurosurg (1991) 2.41
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res (2000) 2.39
DACRYO-CYSTO-RHINOSTOMY. Br J Ophthalmol (1946) 2.32
Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med (1997) 2.32
Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology (2000) 2.27
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res (2000) 2.24
Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice. J Clin Invest (2000) 2.17
A new type of transforming growth factor-beta, TGF-beta 3. EMBO J (1988) 2.12
Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci U S A (1989) 2.09
Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A (1995) 2.07
Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A (1988) 2.03
Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci U S A (1999) 1.96
Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog (1991) 1.95
p27/Kip1 mutation found in breast cancer. Cancer Res (1996) 1.94
Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Gastroenterology (1999) 1.88
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst (1997) 1.88
Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest (1987) 1.88
Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene (2005) 1.81
Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol (1989) 1.78
Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A (1991) 1.77
Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol Cell Biol (1989) 1.76
When and to what end do pathologists agree? J Natl Cancer Inst (1998) 1.76
Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology (1995) 1.74
Production of transforming growth factors by human colon cancer lines. Cancer Res (1986) 1.74
Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer (2001) 1.70
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem (1999) 1.70
Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. J Clin Invest (1989) 1.69
Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol (1987) 1.68
Transforming growth factors and control of neoplastic cell growth. J Cell Biochem (1987) 1.67
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst (1999) 1.67
Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol (1991) 1.65
Stereotactic gamma knife radiosurgery. Initial North American experience in 207 patients. Arch Neurol (1990) 1.64
Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res (1987) 1.61
Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene (2001) 1.59
Isolation of large numbers of fully viable human neutrophils: a preparative technique using percoll density gradient centrifugation. Exp Hematol (1982) 1.59
A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res (1991) 1.58
Flk-1 as a target for tumor growth inhibition. Cancer Res (1996) 1.56
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene (2010) 1.56
Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys (1996) 1.56
Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res (2000) 1.54
Fatal progression of posttraumatic dural arteriovenous fistulas refractory to multimodal therapy. Case report. J Neurosurg (2001) 1.53
Reversible drug-induced oxyntic atrophy in rats. Gastroenterology (2000) 1.53
Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol (1998) 1.52
Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell (2001) 1.52
Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer (1994) 1.50
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene (2011) 1.49
Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol (1998) 1.48
Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc Natl Acad Sci U S A (1996) 1.46
Reactive spindle cell nodules of the breast after core biopsy or fine-needle aspiration. Am J Clin Pathol (2000) 1.45
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res (2001) 1.44
Crk-associated substrate p130(Cas) interacts with nephrocystin and both proteins localize to cell-cell contacts of polarized epithelial cells. Exp Cell Res (2000) 1.42
Cellular proliferation and prognosis in breast cancer: statistical purity versus clinical utility. Hum Pathol (1994) 1.41
Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem (1994) 1.40
Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res (1998) 1.40
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem (1997) 1.38
Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer (1987) 1.37
Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol (1996) 1.36
A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology (1997) 1.35
Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol (1985) 1.34
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res (2000) 1.33
Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J (2001) 1.33
Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res (1992) 1.32
Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor. Release of a predominant N-glycosylated 43-kDa soluble form. J Biol Chem (1998) 1.30
Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras. Cancer Res (1997) 1.27
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem (2000) 1.26
Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor. J Cell Biol (1997) 1.25
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res (1988) 1.25
Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res (1998) 1.24
Basolateral targeting and efficient consumption of transforming growth factor-alpha when expressed in Madin-Darby canine kidney cells. J Biol Chem (1994) 1.22
DNA polymerase beta expression differences in selected human tumors and cell lines. Carcinogenesis (1999) 1.22
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des (2000) 1.21
Increased production of transforming growth factor alpha following acute gastric injury. Gastroenterology (1992) 1.20
Induction of transforming growth factor-alpha expression in human keratinocytes by phorbol esters. J Biol Chem (1989) 1.20